Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCrossRef
Hendrix CW, Minnis A, Guddera V, et al. MTN-001: a Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. Conference on retroviruses and opportunistic infections; Boston, 2011.
Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23(11):1430–47.PubMedCrossRef
Bartholow BN, MacQueen KM, Douglas JM Jr, Buchbinder S, McKirnan D, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr. 1997;16(2):108–15.CrossRef
Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995;9:1079–83.PubMedCrossRef
Giocos G, Kagee A, Swartz L. Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents. AIDS Behav. 2008;12(6):842–51.PubMedCrossRef
Jackson DJ, Martin HL Jr, Bwayo JJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS. 1995;9:1279–83.PubMedCrossRef
Jenkins RA, Chinaworapong S, Morgan PA, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 1998;18:171–7.CrossRef
Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785–93.PubMedCrossRef
MacQueen KM, Vanichseni S, Kitayaporn D, et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:243–51.PubMedCrossRef
Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210–7.PubMedCrossRef
Suhadev M, Nyamathi AM, Swaminathan S, et al. A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res. 2006;124:631–40.PubMed
Sahay S, Mehendale S, Sane S, et al. Correlates of HIV vaccine trial participation: an Indian perspective. Vaccine. 2005;23:1351–8.PubMedCrossRef
Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three US communities. J Acquir Immune Defic Syndr. 2001;26:63–71.PubMed
Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2002;30:503–13.PubMedCrossRef
Vanichseni S, Tappero JW, Pitisuttithum P, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX® B/E HIV vaccine tial, Bangkok, Thailand. AIDS. 2004;18:311–6.PubMedCrossRef
Koblin B, Holte S, Lenderking B, Heagerty P, For the HIVNET vaccine preparedness study protocol team. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr. 2000;24(5):451–7.PubMed
deSouza L, Munday PE. Audit of HIV partner notification in a district general hospital. Int J STD AIDS. 2003;14:854–5.CrossRef
Suhadev M, Nyamathi AM, Swaminathan S, Suresh A, Venkatesan P. Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in south India. AIDS Res Hum Retrovir. 2009;25(2):217–24.PubMedCrossRef
Tarimo EA, Thorson A, Bakari M, Mwami J, Sandstrom E, Kulane A. Willingness to volunteer in a phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania. Glob Health Action. 2009;2:1–7.
Ruzagira E, Wandiembe S, Bufumbo L, et al. Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health. 2009;14(2):196–203.PubMedCrossRef
Aliyu G, Mohammad M, Saidu A, et al. HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria. AIDS Care. 2010;22(10):1277–84.PubMedCrossRef
Etcheverry MF, Lum PJ, Evans JL, et al. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011;29(10):1991–6.PubMedCrossRef
Fincham D, Kagee A, Swartz L. Inhibitors and facilitators of willingness to participate (WTP) in an HIV vaccine trial: construction and initial validation of the Inhibitors and facilitators of willingness to participate scale (WPS) among women at risk for HIV infection. AIDS Care. 2010;22(4):452–61.PubMedCrossRef
Tharawan K, Manopaiboon C, Ellertson C, et al. Women’s willingness to participate in microbide trials in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;28(2):180–6.
Gross M, Buchbinder SP, Celum C, Heagerty P, Seage GR III. Team ftHPSP. Rectal microbicides for U.S. gay men: are clinical trials needed? Are they feasible? Sex Transm Dis. 1998;25(6):296–302.PubMedCrossRef
Guest G, Severy L, von Mollendorf C, Van Damme L. Overcoming recruitment challenges: lessons learned from a safety and feasibility study of a diaphragm/microbicide combination in South Africa (Letter to the Editor). J Acquir Immune Defic Syndr. 2007;45(4):481–2.PubMedCrossRef
Ma M, Kibler JL, Vigil-Otero A, Sarpong D, Lally M, Mayer KH. Correlates of willingness to participate in microbicide research among African Americans. J Health Psychol. 2012; Feb 24 [Epub ahead of print].
van de Wijgert J, Coetzee N, de Kock A, Blanchard K, Jones H. Assessing selection bias in a microbicide trial. Poster presentation at the international congress of sexually transmitted infections—ISSTDR/IUSTI, Berlin,June 2001.
Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Aquir Immune Defic Syndr. 2004;36(1):604–12.CrossRef
NACO. HIV Sentinel Surveillance and HIV Estimation in India 2007: a technical brief. New Delhi: National AIDS Control Organisaion, Ministry of Health and Family Welfare, Government of India. October 2008.
NACO. HIV Fact Sheets: based on HIV Sentinel Surveillance Data in India 2003–2006. New Delhi: National AIDS Control Organisation, Ministry of Health and Family Welfare. November 2007.
Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl 2):S67–72.PubMedCrossRef
Abdul-Quader AS, Heckathorn DD, Sabin K, Saidel T. Implementation and analysis of respondent driven sampling: lessons learned from the field. J Urban Health. 2006;83(Suppl 7):i1–5.PubMedCrossRef
Tun W, Sarna A, Apicella L, Bhattacharya A. Recruitment of injecting drug users in two cities in India using respondent driven sampling for an HIV-related behavioral survey. In: 2nd international conference on surveying health in complex situations, 4 June 2007, University of Louvain, Belgium.
Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.CrossRef
Heckathorn DD, Semaan S, Broadhead RS, Hughes JJ. Extensions of respondent-driven sampling: a new approach to the study of injection drug users aged 18–25. AIDS Behav. 2002;6(1):55–67.CrossRef
Tun W, Katzen LL, Abbott SA, et al. Using a 2-stage strategy with respondent-driven sampling to recruit a hard-to-reach population for a placebo microbicide gel clinical trial in Nellore, Andhra Pradesh (India). 2011. Unpublished.
Abbott SA, Friedland BA, Sarna A, et al. An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. 2011. Unpublished.
Filmer D, Pritchett LH. Estimating wealth effects without expenditure data, or tears: an application to educational enrollments in states of India. Demography. 2001;38(1):115–32.PubMed
Woodsong C, Alleman P, Musara P, et al. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2011. doi:10.1007/s10461-011-0027-7
Microbicide Trials Network (MTN). Expanded safety and acceptability study of a non-medicated intravaginal ring. Microbicide trials network. http://www.mtnstopshiv.org/studies/72
. Accessed 30 March 2012.
Coetzee N, Blanchard K, Ellertson C, Hoosen AA, Friedland B. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS. 2001;15(14):1837–42.PubMedCrossRef
Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.PubMedCrossRef
Mensch BS, Hewett PC, Abbott S, et al. Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav. 2011;15(2):407–21.PubMedCrossRef
Microbicide Trials Network (MTN). MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3619
.Accessed 14 Oct 2011.
Thigpen MC, Kaebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Presentation given at international AIDS society conference, 17–20 July 2011, Rome. Oral abstract WELBC01.
Baeten J, Celum C, on behalf of the partners PrEP study team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Presentation given at International AIDS Society conference. 17–20 July 2011, Rome. Oral Abstract MOAX0106.